WO2012070861A3 - 위암 진단을 위한 위암 특이적 메틸화 바이오마커 - Google Patents

위암 진단을 위한 위암 특이적 메틸화 바이오마커 Download PDF

Info

Publication number
WO2012070861A3
WO2012070861A3 PCT/KR2011/008963 KR2011008963W WO2012070861A3 WO 2012070861 A3 WO2012070861 A3 WO 2012070861A3 KR 2011008963 W KR2011008963 W KR 2011008963W WO 2012070861 A3 WO2012070861 A3 WO 2012070861A3
Authority
WO
WIPO (PCT)
Prior art keywords
stomach cancer
diagnosis
methylation
gene
genbank
Prior art date
Application number
PCT/KR2011/008963
Other languages
English (en)
French (fr)
Other versions
WO2012070861A2 (ko
Inventor
안성환
문영호
노승무
송규상
윤치왕
오태정
김명순
오명석
Original Assignee
(주)지노믹트리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)지노믹트리 filed Critical (주)지노믹트리
Publication of WO2012070861A2 publication Critical patent/WO2012070861A2/ko
Publication of WO2012070861A3 publication Critical patent/WO2012070861A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

본 발명은 위암 진단을 위한, 위암 특이적인 바이오마커 유전자의 메틸화 검출방법에 관한 것으로, 더욱 자세하게는 위암 세포에서 특정 유전자의 CpG 섬 부위가 특이적으로 메틸화되는 위암 특이적 바이오마커의 메틸화를 검출하여 위암 진단을 위한 정보를 제공하는 방법에 관한 것이다. 본 발명에 따른 NTRK3 (GenBank NM_001007156, neurotrophic tyrosine kinase, receptor, type 3) 또는 AFF2 (GenBank NM_002025, AF4/ FMR2 family, member 2) 유전자의 CpG 섬의 메틸화 검출방법을 이용하면, 위암을 초기 형질전환 단계에서 진단할 수 있어, 조기진단이 가능하고 통상적인 방법보다 정확하고 빠르게 위암 및 위암의 진행단계를 진단할 수 있다.
PCT/KR2011/008963 2010-11-24 2011-11-23 위암 진단을 위한 위암 특이적 메틸화 바이오마커 WO2012070861A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100117372A KR101284014B1 (ko) 2010-11-24 2010-11-24 위암 진단을 위한 위암 특이적 메틸화 바이오마커
KR10-2010-0117372 2010-11-24

Publications (2)

Publication Number Publication Date
WO2012070861A2 WO2012070861A2 (ko) 2012-05-31
WO2012070861A3 true WO2012070861A3 (ko) 2012-07-19

Family

ID=46146298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/008963 WO2012070861A2 (ko) 2010-11-24 2011-11-23 위암 진단을 위한 위암 특이적 메틸화 바이오마커

Country Status (2)

Country Link
KR (1) KR101284014B1 (ko)
WO (1) WO2012070861A2 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9797017B2 (en) 2007-11-30 2017-10-24 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9670551B2 (en) 2007-11-30 2017-06-06 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US10113203B2 (en) 2007-11-30 2018-10-30 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9670552B2 (en) 2007-11-30 2017-06-06 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9783857B2 (en) 2007-11-30 2017-10-10 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9752197B2 (en) 2010-12-16 2017-09-05 Genomictree, Inc. Method for detecting methylation of colorectal cancer specific methylation marker gene for colorectal cancer diagnosis
US10428390B2 (en) 2010-12-16 2019-10-01 Genomictree, Inc. Method for detecting methylation of colorectal cancer specific methylation marker gene for colorectal cancer diagnosis
US10428389B2 (en) 2010-12-16 2019-10-01 Genomictree, Inc. Method for detecting methylation of colorectal cancer specific methylation marker gene for colorectal cancer diagnosis
KR101569498B1 (ko) * 2012-11-07 2015-11-16 (주)지노믹트리 위용종 및 위암 특이적 메틸화 마커 유전자를 이용한 위용종 및 위암의 검출방법
JP2016192909A (ja) * 2015-03-31 2016-11-17 シスメックス株式会社 胃癌に関する情報の取得方法、ならびに胃癌に関する情報を取得するためのマーカーおよび胃癌検出用キット
KR101755613B1 (ko) 2015-05-19 2017-07-10 한국과학기술연구원 뉴로텐신 수용체의 활성을 이용하여 위암 치료용 물질을 스크리닝하는 방법
KR101959538B1 (ko) * 2017-05-29 2019-03-20 대한민국 CpG 아일랜드 예측 및 프라이머 제작을 위한 파이프라인 방법
AU2019200359A1 (en) * 2019-01-18 2020-09-10 Clinical Genomics Pty Ltd Screening method
CN115044671A (zh) * 2021-03-09 2022-09-13 广州市基准医疗有限责任公司 可用于胃癌her2伴随诊断的基因甲基化标记物或其组合和应用
WO2024001602A1 (zh) * 2022-07-01 2024-01-04 圣湘生物科技股份有限公司 一种用于检测胃癌的组合物，试剂盒及其用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANG, P. W. ET AL.: "Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features", BMC CANCER., vol. 10, 21 May 2010 (2010-05-21), pages 227, XP021075066, DOI: doi:10.1186/1471-2407-10-227 *
OBATA, T. ET AL.: "Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer", CLINICAL CANCER RESEARCH., vol. 9, no. 17, 15 December 2003 (2003-12-15), pages 6410 - 6418, XP055013678 *
PARK, J. ET AL.: "Aberrant methylation of intergrin alpha4 gene in human gastric cancer cells", ONCOGENE, vol. 23, no. 19, 22 April 2004 (2004-04-22), pages 3474 - 3480, XP055030397, DOI: doi:10.1038/sj.onc.1207470 *
WAKI, T. ET AL.: "Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia", CANCER SCIENCE., vol. 94, no. 4, April 2003 (2003-04-01), pages 360 - 364 *
WOOD, L. D. ET AL.: "Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers", HUMAN MUTATION., vol. 27, no. 10, October 2006 (2006-10-01), pages 1060 - 1061, XP055044709, DOI: doi:10.1002/humu.9452 *

Also Published As

Publication number Publication date
KR20120055917A (ko) 2012-06-01
WO2012070861A2 (ko) 2012-05-31
KR101284014B1 (ko) 2013-07-09

Similar Documents

Publication Publication Date Title
WO2012070861A3 (ko) 위암 진단을 위한 위암 특이적 메틸화 바이오마커
WO2009069984A3 (en) Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
WO2011055916A3 (ko) 장암 진단을 위한 장암 특이적 메틸화 마커 유전자의 메틸화 검출방법
NZ601079A (en) Methods and compositions for noninvasive prenatal diagnosis of fetal aneuploidies
WO2009114543A3 (en) Nucleic acid-based tests for prenatal gender determination
Ribal et al. Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study
WO2012080754A3 (en) Oligonucleotide probe set and methods of microbiota profiling
WO2009115615A3 (en) Detection and prognosis of cervical cancer
WO2012096523A3 (en) Detection of target nucleic acid sequences by pto cleavage and extension assay
WO2012006632A3 (en) Lung cancer biomarkers and uses thereof
WO2011056489A3 (en) Diagnostic methods for determining prognosis of non-small cell lung cancer
WO2006133923A3 (en) Diagnosis, prognosis and prediction of recurrence of breast cancer
WO2012021795A3 (en) Pancreatic cancer biomarkers and uses thereof
EP2611941A4 (en) GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
WO2012177945A3 (en) Diagnostic methods for eosinophilic esophagitis
WO2008087040A3 (en) Methods and nucleic acids for analyses of cell proliferative disorders
WO2013057581A8 (en) Composite biomarker for non-invasive screening, diagnosis and prognosis of colorectal cancer
WO2013148147A8 (en) Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
JP2011515091A5 (ko)
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
GB2464647A (en) An assay to detect a gynecological condition
WO2011044541A3 (en) Identification of micrornas (mirnas) in fecal samples as biomarkers for gastroenterological cancers
WO2010034794A3 (en) Methods and kits for the diagnosis and the staging of colorectal cancer
WO2009074328A8 (en) Methods and nucleic acids for analyses of lung carcinoma
WO2013023144A3 (en) Diagnostic biomarker profiles for the detection and diagnosis of parkinsons disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11843144

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11843144

Country of ref document: EP

Kind code of ref document: A2